You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Adults (= 18 Years)
Primary Hypercholesterolaemia,AKM EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor (statin), is
indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and
non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE, administered with a statin, is indicated for patients with HoFH. Patients
may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),AKM EZETIMIBE is indicated for the reduction of elevated sitosterol and campesterol levels
in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,AKM EZETIMIBE, is indicated for administration in combination with the maximum
tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart
disease (CHD) and a history of acute coronary syndrome (ACS) in need of additional
lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated as an
adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial
hypercholesterolaemia where use of a combination product is appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated in
adolescent patients (10-17 years old) with HoFH. Patients may also receive adjunctive
treatments (e.g. LDL apheresis)
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults (= 18 Years)
Primary Hypercholesterolaemia,AKM EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor (statin), is
indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and
non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE, administered with a statin, is indicated for patients with HoFH. Patients
may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),AKM EZETIMIBE is indicated for the reduction of elevated sitosterol and campesterol levels
in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,AKM EZETIMIBE, is indicated for administration in combination with the maximum
tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart
disease (CHD) and a history of acute coronary syndrome (ACS) in need of additional
lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated as an
adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial
hypercholesterolaemia where use of a combination product is appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated in
adolescent patients (10-17 years old) with HoFH. Patients may also receive adjunctive
treatments (e.g. LDL apheresis)
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults (= 18 Years)
Primary Hypercholesterolaemia,AKM EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor (statin), is
indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and
non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE, administered with a statin, is indicated for patients with HoFH. Patients
may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),AKM EZETIMIBE is indicated for the reduction of elevated sitosterol and campesterol levels
in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,AKM EZETIMIBE, is indicated for administration in combination with the maximum
tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart
disease (CHD) and a history of acute coronary syndrome (ACS) in need of additional
lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated as an
adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial
hypercholesterolaemia where use of a combination product is appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated in
adolescent patients (10-17 years old) with HoFH. Patients may also receive adjunctive
treatments (e.g. LDL apheresis)
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults (= 18 Years)
Primary Hypercholesterolaemia,AKM EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor (statin), is
indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and
non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE, administered with a statin, is indicated for patients with HoFH. Patients
may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),AKM EZETIMIBE is indicated for the reduction of elevated sitosterol and campesterol levels
in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,AKM EZETIMIBE, is indicated for administration in combination with the maximum
tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart
disease (CHD) and a history of acute coronary syndrome (ACS) in need of additional
lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated as an
adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial
hypercholesterolaemia where use of a combination product is appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),AKM EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is indicated in
adolescent patients (10-17 years old) with HoFH. Patients may also receive adjunctive
treatments (e.g. LDL apheresis)
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
